Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Vandana Singh

Eli Lilly Achieves 80% Jump In COVID-19 Therapy Sales, Revises FY22 Guidance

  • Eli Lilly And Co (NYSE:LLY) has posted Q1 sales of $7.8 billion, beating the consensus of $6.68 billion.
  • Lilly's revenue increased 15%, driven by volume growth of 20%, partially offset by a 3% decrease due to lower realized prices and a 2% decrease due to the unfavorable impact of foreign exchange rates. 
  • Excluding revenue from COVID-19 antibodies and Alimta, Q1 2022 revenue grew 10%.
  • Key growth products, consisting of Trulicity, Verzenio, Jardiance, Taltz, Olumiant, Emgality, Retevmo, Cyramza, and Tyvyt, contributed 13 percentage points of revenue growth.
  • Trulicity sales jumped 20% to $1.74 billion.
  • Revenue from COVID-19 antibodies reached $1.47 billion compared with $810.1 million in Q1 2021.
  • The adjusted gross margin was 76.1%, an increase of 0.7 percentage points from a year ago. The adjusted operating margin reached 33.4%.
  • Adjusted EPS increased 63% Y/Y to $2.62, ahead of the consensus of $2.13.
  • FY22 guidance: Eli Lilly anticipates revenue of $28.8 billion - $29.3 billion, better than the earlier outlook of $27.8 billion - $28.3 billion, compared to the consensus of $24.88 billion.
  • The guidance reflects additional COVID-19 antibodies revenue from selling 600,000 doses of bebtelovimab to the U.S. government in Q1 2022.
  • Lilly sees adjusted EPS as $8.15 - $8.30, down from prior guidance of $8.50 - $8.65, versus the consensus of $8.19.
  • Price Action: LLY shares are up 2.66% at $292.67 during the market session on the last check Thursday.
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.